UNLIMITED TURBO LONG - NOVO-NORDISK B | Real-time Borsa Italiana 05:54:29 03/06/2024 pm IST | ||
| 4.89 EUR | -3.93% |
|
| 1 month | +9.46% | ||
| 3 months | +35.37% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 4.89 | -3.93% |
| 31/24/31 | 5.09 | +2.83% |
| 30/24/30 | 4.95 | +0.81% |
| 29/24/29 | 4.91 | -1.21% |
| 28/24/28 | 4.97 | -1.00% |
Real-time Borsa Italiana
Last update June 03, 2024 at 05:54 pm IST
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| P1UKU6 | |
| ISIN | NLBNPIT1UKU6 |
| Date issued | 22/09/2023 |
| Strike | 572 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.28 € |
|---|---|
| Lowest since issue | 1.279 € |
| Spread | 0.01 € |
| Spread % | 0.20% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- P1UKU6 Certificat
